1st Dec 2022 07:45
Arix Bioscience plc("Company")
PDMR notification & Director Shareholding
The Company announces the annual award of nil cost options to CEO Robert Lyne, which are subject to performance conditions over a three-year assessment period from 1 January 2022 to 31 December 2024 in accordance with the Company's Executive Incentive Plan ("EIP") as disclosed in the Company's Remuneration Policy ("Policy"). Vested Shares are subject to a further two year holding period, as set out in the Policy.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Robert Lyne | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Executive Officer | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a)
| Name
| Arix Bioscience plc | |||
b)
| LEI
| 213800OVT3AHQCXNIX43
| |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a)
| Description of the financial instrument, type of instrument | Arix Bioscience plc Ordinary shares of 0.001 pence each | |||
Identification code | GB00BD045071 | ||||
b)
| Nature of the transaction
| Award of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP") | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
Nil
| 636,792 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | N/A (Single Transaction) | ||||
- Price | N/A (Single Transaction) | ||||
e)
| Date of the transaction
| 30 November 2022 | |||
f)
| Place of the transaction
| Outside a trading venue | |||
For further information please contact:Kin Company Secretarial Limited, Company Secretary +44 20 8819 6486
Related Shares:
ARIX.L